Previous 10 | Next 10 |
Cellular Biomedicine Group, Inc. (CBMG) Q1 2019 Earnings Conference Call May 1, 2019 08:30 AM ET Company Participants Tony Liu - Executive Director, CEO, CFO Derrick Li - Head of Strategy & IR Conference Call Participants Madhu Kumar - Robert W. Baird George Zavoico - B...
Cellular Biomedicine (NASDAQ: CBMG ): Q1 GAAP EPS of -$0.51 beats by $0.09 . More news on: Cellular Biomedicine Group, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
NEW YORK and SHANGHAI , April 30, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc . (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today r...
NEW YORK and SHANGHAI , April 29, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today ...
NEW YORK and SHANGHAI , April 25, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced...
NEW YORK , April 23, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it re...
NEW YORK , April 15, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc . (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that Tony ...
NEW YORK , April 5, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc . (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that Derri...
NEW YORK and SHANGHAI , March 28, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc . (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announc...
Cellular Biomedicine Group (NASDAQ: CBMG ) prices its public offering of 1,029,412 common stock at a price of $17.00/share, for gross proceeds of ~$17.5M. More news on: Cellular Biomedicine Group, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Cellular Biomedicine Group Inc. Company Name:
CBMG Stock Symbol:
NASDAQ Market:
Cellular Biomedicine Group Inc. Website:
Cellular Biomedicine Group, Inc. Announces Completion of Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Feb. 19, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") today announced the completion of the merger (th...
Cellular Biomedicine Group, Inc. Stockholders Approve Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Feb. 8, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") announced that, at the Company's special meeting...
Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Jan. 28, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company,...